Stansbury Robert C, Strollo Patrick J
1 Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, West Virginia University School of Medicine, Morgantown, West Virginia, USA ; 2 Division of Pulmonary, Allergy, and Critical Care Medicine, UPMC Sleep Medicine Center, Montefiore Hospital, Pittsburgh, PA, USA.
J Thorac Dis. 2015 Sep;7(9):E298-310. doi: 10.3978/j.issn.2072-1439.2015.09.13.
Obstructive sleep apnea (OSA) may manifest in a number of ways from subtle intrusion into daily life to profound sleepiness, snoring, witnessed apneas and other classic symptoms. Although there is increasing evidence suggesting OSA can adversely affect health in a variety of ways, this disorder remains underdiagnosed. The most well-escribed health consequences of OSA relate to the cardiovascular system. Hypertension and arrhythmias have a strong association with OSA, and evidence suggests that treatment of OSA in patients with refractory hypertension and in patients planning cardioversion for atrial fibrillation may be of particularly importance. Significant associations between heart failure and OSA as well as complex sleep apnea have also been well-described. Cerebrovascular insult, impaired neurocognition, and poorly controlled mood disorder are also associated with in OSA. Therapy for OSA may ameliorate atherosclerotic progression and improve outcomes post-cerebrovascular accident (CVA). OSA should be considered in patients complaining of poor concentration at work, actual or near-miss motor vehicle accidents, and patients with severe sleepiness as a component of their co-morbid mood disorders. The metabolic impact of OSA has also been studied, particularly in relation to glucose homeostasis. Also of interest is the potential impact OSA has on lipid metabolism. The adverse effect untreated OSA has on glucose tolerance and lipid levels has led to the suggestion that OSA is yet another constituent of the metabolic syndrome. Some of these metabolic derangements may be related to the adverse effects untreated OSA has on hepatic health. The cardiovascular, neurocognitive, and metabolic manifestations of OSA can have a significant impact on patient health and quality of life. In many instances, evidence exists that therapy not only improves outcomes in general, but also modifies the severity of co-morbid disease. To mitigate the long-term sequela of this disease, providers should be aware of the subtle manifestations of OSA and order appropriate testing as necessary.
阻塞性睡眠呼吸暂停(OSA)可能以多种方式表现出来,从对日常生活的轻微干扰到严重嗜睡、打鼾、观察到的呼吸暂停及其他典型症状。尽管越来越多的证据表明OSA会以多种方式对健康产生不利影响,但这种疾病仍未得到充分诊断。OSA最广为人知的健康后果与心血管系统有关。高血压和心律失常与OSA密切相关,有证据表明,对于难治性高血压患者以及计划进行房颤复律的患者,治疗OSA可能尤为重要。心力衰竭与OSA以及复杂性睡眠呼吸暂停之间的显著关联也有详细描述。脑血管损伤、神经认知功能受损和情绪障碍控制不佳也与OSA有关。OSA的治疗可能会改善动脉粥样硬化进展,并改善脑血管意外(CVA)后的预后。对于抱怨工作时注意力不集中、发生实际或险些发生的机动车事故的患者,以及患有严重嗜睡且将其作为共病情绪障碍一部分的患者,应考虑OSA。OSA的代谢影响也已得到研究,特别是与葡萄糖稳态相关的影响。OSA对脂质代谢的潜在影响也备受关注。未经治疗的OSA对葡萄糖耐量和血脂水平的不利影响表明,OSA是代谢综合征的另一个组成部分。其中一些代谢紊乱可能与未经治疗的OSA对肝脏健康的不利影响有关。OSA的心血管、神经认知和代谢表现会对患者的健康和生活质量产生重大影响。在许多情况下,有证据表明治疗不仅能总体上改善预后,还能改变共病疾病的严重程度。为了减轻这种疾病的长期后遗症,医疗服务提供者应了解OSA的细微表现,并在必要时安排适当的检查。